复发或转移性头颈部鳞状细胞癌患者的生存结果和缓解率。
Survival outcomes and response rates among patients with recurrent or metastatic head and neck squamous cell carcinoma.
作者信息
Allurkar Soumya, Patadiya Hiren Hansraj, Marmat Himani, Kundu Debapriya, Tulsi Satinder Pal Singh, Gupta Satya Prakash
机构信息
Department Oral and Maxillofacial Surgery, PMNM Dental College and Hospital, Bagalkot, Karnataka, India.
Dental Practice, My Dental Southbridge, 305 Main st Southbridge, MA, USA-01550.
出版信息
Bioinformation. 2025 Jan 31;21(1):44-47. doi: 10.6026/973206300210044. eCollection 2025.
Abstract
Evaluation of survival outcomes and response rates among patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) treated with checkpoint inhibitors is of interest. Data regarding overall survival (OS), progression free survival (PFS), response rate, PD-L1 combined positive score (CPS) was retrieved. A total of 412 patients with histo-pathologically confirmed recurrent or metastatic HNSCC who received checkpoint inhibitor (CPI) treatment were ultimately included as members of the cohort. The median overall survival was 13.1 months. Median PFS was 4.1 months. The estimated 1-year overall survival was 53.9% while estimated 1-year PFS was 9.7%. Thus, the use of CPI therapies for first - or second-line treatment of recurrent or metastatic head and neck squamous cell carcinoma is shown.
摘要
对接受检查点抑制剂治疗的复发或转移性头颈部鳞状细胞癌（HNSCC）患者的生存结果和缓解率进行评估具有重要意义。检索了有关总生存期（OS）、无进展生存期（PFS）、缓解率、PD-L1联合阳性评分（CPS）的数据。共有412例经组织病理学确诊为复发或转移性HNSCC且接受检查点抑制剂（CPI）治疗的患者最终被纳入该队列。中位总生存期为13.1个月。中位PFS为4.1个月。估计1年总生存率为53.9%，而估计1年PFS为9.7%。因此，显示了CPI疗法用于复发或转移性头颈部鳞状细胞癌一线或二线治疗的情况。
相似文献
1
Survival outcomes and response rates among patients with recurrent or metastatic head and neck squamous cell carcinoma.复发或转移性头颈部鳞状细胞癌患者的生存结果和缓解率。
Bioinformation. 2025 Jan 31;21(1):44-47. doi: 10.6026/973206300210044. eCollection 2025.
2
Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.程序性细胞死亡受体 1（PD-1）抑制剂联合同期放化疗治疗复发性/转移性头颈部鳞状细胞癌患者的协同作用的初步分析。
Radiat Oncol. 2023 Jul 4;18(1):109. doi: 10.1186/s13014-023-02310-8.
3
Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors.接受检查点抑制剂治疗的头颈部黏膜鳞状细胞癌患者的结局。
JAMA Otolaryngol Head Neck Surg. 2022 Oct 1;148(10):918-926. doi: 10.1001/jamaoto.2022.2284.
4
Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.头颈部鳞状细胞癌中的免疫检查点抑制剂：3期临床试验的系统评价
World J Clin Oncol. 2022 May 24;13(5):388-411. doi: 10.5306/wjco.v13.i5.388.
5
Evaluating the efficacy and safety of immune checkpoint inhibitors in first and second-line treatments for recurrent and metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis of RCTs with a focus on PD-L1 expression.评估免疫检查点抑制剂在复发性和转移性头颈部鳞状细胞癌一线及二线治疗中的疗效和安全性：一项针对随机对照试验的系统评价和网状荟萃分析，重点关注程序性死亡受体 1 配体（PD-L1）表达情况
Front Immunol. 2025 Feb 13;16:1508885. doi: 10.3389/fimmu.2025.1508885. eCollection 2025.
6
Relationship Between Short-Term Outcomes and PD-L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated With Anti-PD-1 Antibody Monotherapy.基于联合阳性评分和肿瘤比例评分的抗PD-1抗体单药治疗复发性或转移性头颈癌的短期疗效与PD-L1表达的关系
Cancer Rep (Hoboken). 2025 Jan;8(1):e70125. doi: 10.1002/cnr2.70125.
7
"Off-Label" Use of Checkpoint Inhibitors in Patients With Negative or Unknown PD-L1 Status in Advanced Head and Neck Cancer.晚期头颈癌中程序性死亡配体1（PD-L1）状态为阴性或未知的患者使用检查点抑制剂的“超说明书”应用
J Natl Compr Canc Netw. 2025 Feb 11;23(3):90-96. doi: 10.6004/jnccn.2024.7085.
8
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.帕博利珠单抗单药或联合化疗对比西妥昔单抗联合化疗用于治疗复发性或转移性头颈部鳞状细胞癌（KEYNOTE-048）：一项随机、开放标签、III 期研究。
Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.
9
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.度伐利尤单抗治疗复发或转移性头颈部鳞状细胞癌：在肿瘤细胞 PD-L1 表达≥25%且在铂类化疗后进展的患者中进行的一项单臂、Ⅱ期研究结果。
Eur J Cancer. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18.
10
A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis.一种基于 Pan-Immune-Inflammation 值和程序性死亡配体 1 的新型预后模型在接受免疫检查点抑制剂治疗的复发性或转移性头颈部鳞状细胞癌患者中的应用：一项回顾性多中心分析。
Target Oncol. 2024 Jan;19(1):71-79. doi: 10.1007/s11523-023-01018-9. Epub 2023 Dec 2.
本文引用的文献
1
Recurrent Versus Metastatic Head and Neck Cancer: An Evolving Landscape and the Role of Immunotherapy.复发性与转移性头颈癌：不断演变的格局及免疫治疗的作用
Biomedicines. 2024 Sep 12;12(9):2080. doi: 10.3390/biomedicines12092080.
2
Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC.ICI 治疗复发性或转移性头颈部鳞状细胞癌的总生存期、治疗持续时间和再挑战结果。
JAMA Netw Open. 2024 Aug 1;7(8):e2428526. doi: 10.1001/jamanetworkopen.2024.28526.
3
Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma.探讨复发性和转移性头颈部鳞状细胞癌对免疫检查点抑制剂的长期反应。
Oral Oncol. 2024 Feb;149:106664. doi: 10.1016/j.oraloncology.2023.106664. Epub 2023 Dec 18.
4
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer.免疫治疗持续时间与晚期非小细胞肺癌患者总生存期的相关性。
JAMA Oncol. 2023 Aug 1;9(8):1075-1082. doi: 10.1001/jamaoncol.2023.1891.
5
Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan.派姆单抗方案作为复发性/转移性头颈部鳞状细胞癌一线治疗的真实世界治疗结果：日本单中心回顾性队列研究。
Anticancer Res. 2022 Sep;42(9):4477-4484. doi: 10.21873/anticanres.15948.
6
Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors.接受检查点抑制剂治疗的头颈部黏膜鳞状细胞癌患者的结局。
JAMA Otolaryngol Head Neck Surg. 2022 Oct 1;148(10):918-926. doi: 10.1001/jamaoto.2022.2284.
7
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.免疫检查点抑制剂（ICI）治疗超过 18 个月后在晚期非小细胞肺癌（NSCLC）真实世界患者中的停药：INTEPI，一项多中心回顾性研究。
Cancer Immunol Immunother. 2022 Jul;71(7):1719-1731. doi: 10.1007/s00262-021-03114-z. Epub 2021 Nov 25.
8
Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.免疫相关不良反应与接受免疫检查点抑制剂的头颈部癌症患者的反应改善、无进展生存期和总生存期相关。
Cancer. 2021 Dec 15;127(24):4565-4573. doi: 10.1002/cncr.33780. Epub 2021 Sep 21.
9
Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.复发性和/或转移性头颈部癌患者采用化疗联合西妥昔单抗作为一线治疗的生存预测因素和结局：一项真实世界的回顾性研究。
Cancer Treat Res Commun. 2021;27:100375. doi: 10.1016/j.ctarc.2021.100375. Epub 2021 Apr 14.
10
Considerations for treatment duration in responders to immune checkpoint inhibitors.考虑免疫检查点抑制剂应答者的治疗持续时间。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001901.
Zotero 插件